The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Unanswered questions in CAR-T therapies
Jennifer Brudno, MD, National Cancer Institute, Bethesda, MD, explores unanswered questions regarding chimeric antigen receptor (CAR) T-cell therapies in hematologic malignancies. Commercially available CAR T-cell therapies such as idecabtagene vicleucel and axicabtagene ciloleucel were tested in pre-treated patients in clinical trials, opening up the possibility of using CAR T-cell therapy in earlier lines of treatment. Dr Brudno suggests that administering CAR T-cell therapies earlier may increase efficacy due to patients being exposed less to prior chemotherapy and consequently having a more robust immune system. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
